{"trials":[{"id":3686,"nct_id":"NCT07610135","title":"PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07610135","tracker_url":"publication.php?id=3686","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-10-30","primary_completion_date":"2028-06","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Mood (Psychological Function)","Well Being","Mood","Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Inactive Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3709,"nct_id":"NCT07180108","title":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07180108","tracker_url":"publication.php?id=3709","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2025-08-12","primary_completion_date":"2028-06","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psilocybin","Music Intervention"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Playlist 1","type":"BEHAVIORAL"},{"name":"Playlist 2","type":"BEHAVIORAL"},{"name":"Playlist 3","type":"BEHAVIORAL"},{"name":"Playlist 4","type":"BEHAVIORAL"},{"name":"Playlist 5","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3525,"nct_id":"NCT07565493","title":"Psilocybin Administration With 5-HT1a Blockade","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07565493","tracker_url":"publication.php?id=3525","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-14","start_date":"2026-08-12","primary_completion_date":"2028-06-15","completion_date":"2028-06-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Pindolol","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3651,"nct_id":"NCT05546658","title":"Effects of Psilocybin in Obsessive Compulsive Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05546658","tracker_url":"publication.php?id=3651","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2022-11-28","primary_completion_date":"2026-12-30","completion_date":"2027-09-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":35,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3604,"nct_id":"NCT04123314","title":"Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04123314","tracker_url":"publication.php?id=3604","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2021-03-24","primary_completion_date":"2027-06-30","completion_date":"2027-09-30","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depressive Symptoms","Depression","Alzheimer Disease","Mild Cognitive Impairment"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3590,"nct_id":"NCT06355414","title":"Psilocybin and Affective Function in Chronic Lower Back Pain Depression","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06355414","tracker_url":"publication.php?id=3590","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-04-22","primary_completion_date":"2026-12-30","completion_date":"2026-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Low-back Pain","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3552,"nct_id":"NCT06989957","title":"Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06989957","tracker_url":"publication.php?id=3552","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2025-09-17","primary_completion_date":"2028-08","completion_date":"2029-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Posttraumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"MDMA","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3602,"nct_id":"NCT06450210","title":"Safety for Home Administration of Microdose Psilocybin Use","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06450210","tracker_url":"publication.php?id=3602","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-08-14","start_date":"2024-12-06","primary_completion_date":"2026-07-31","completion_date":"2026-07-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Psychedelic Experiences"],"interventions":[{"name":"psilocybin trihydrate","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e3da1ce8cb4b14f80a762b6f6cadb84535f4c69b15786b698ef1c7179aa721b3","facility":"5510 Nathan Shock Drive","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3523,"nct_id":"NCT06656702","title":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06656702","tracker_url":"publication.php?id=3523","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-11","start_date":"2025-04-09","primary_completion_date":"2027-01-30","completion_date":"2027-07-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3533,"nct_id":"NCT06835699","title":"Open Label Psilocybin Brain Stimulation and Imaging Pilot Study","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06835699","tracker_url":"publication.php?id=3533","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-08-07","start_date":"2025-04-18","primary_completion_date":"2026-05-21","completion_date":"2026-05-21","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin 25 mgs","type":"DRUG"},{"name":"TMS","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"4c399ae21c1b15c1a76957dcb18c09f6ab07051151f994333e7109fd67ba663d","facility":"Johns Hopkins School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3707,"nct_id":"NCT05301608","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05301608","tracker_url":"publication.php?id=3707","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2022-03-03","primary_completion_date":"2026-12-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3691,"nct_id":"NCT06067737","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06067737","tracker_url":"publication.php?id=3691","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-17","start_date":"2024-02-08","primary_completion_date":"2028-07","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3494,"nct_id":"NCT05452772","title":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05452772","tracker_url":"publication.php?id=3494","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-29","start_date":"2023-11-01","primary_completion_date":"2026-12","completion_date":"2027-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":66,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Tobacco Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3471,"nct_id":"NCT06407635","title":"Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06407635","tracker_url":"publication.php?id=3471","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-22","start_date":"2024-06-07","primary_completion_date":"2026-03-09","completion_date":"2027-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Trauma-focused psychotherapy","type":"OTHER"},{"name":"Standard psychological support","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3643,"nct_id":"NCT06660381","title":"Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06660381","tracker_url":"publication.php?id=3643","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2024-11-08","primary_completion_date":"2026-11","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cannabis Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3493,"nct_id":"NCT04620759","title":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04620759","tracker_url":"publication.php?id=3493","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-13","start_date":"2021-04-14","primary_completion_date":"2026-03-02","completion_date":"2027-03-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3675,"nct_id":"NCT06005662","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06005662","tracker_url":"publication.php?id=3675","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2026-02","last_update_date":"2026-02-23","start_date":"2027-04","primary_completion_date":"2028-07","completion_date":"2028-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"be5d63bf40aada157fda0af485fadeddd7eac0c079ecab26a1612289fb4c7fdb","facility":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3551,"nct_id":"NCT06772753","title":"Investigation of Psychedelic Effects in Psychoactive Substances","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06772753","tracker_url":"publication.php?id=3551","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-23","start_date":"2025-02-05","primary_completion_date":"2027-06","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"},{"name":"Dextromethorphan (DXM)","type":"DRUG"},{"name":"Dimethyltryptamine (DMT)","type":"DRUG"},{"name":"Methylenedioxymethamphetamine (MDMA)","type":"DRUG"},{"name":"Tetrahydrocannabinol (THC)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3425,"nct_id":"NCT07053917","title":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07053917","tracker_url":"publication.php?id=3425","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-13","start_date":"2026-02-09","primary_completion_date":"2027-02","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and/or Hemiparesis Following Stroke","Middle Cerebral Artery Stroke"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3505,"nct_id":"NCT05305105","title":"Effects of Psilocybin in Post-Treatment Lyme Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05305105","tracker_url":"publication.php?id=3505","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-08","last_update_date":"2025-08-20","start_date":"2022-07-01","primary_completion_date":"2024-10-26","completion_date":"2025-04-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Treatment Lyme Disease","Chronic Lyme Disease","Lyme Disease, Chronic"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3655,"nct_id":"NCT01943994","title":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT01943994","tracker_url":"publication.php?id=3655","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-05-25","start_date":"2008-09","primary_completion_date":"2023-05-01","completion_date":"2023-11-14","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":82,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Nicotine Dependence"],"interventions":[{"name":"Psilocybin-assisted treatment","type":"DRUG"},{"name":"Nicotine Replacement Therapy (NRT)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f728406bf268c1157eadcec1c17036ddef288c0c8a17b0883ee337abaeaac4bc","facility":"Neuroimaging Research Branch, NIDA-IRP","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3545,"nct_id":"NCT02243813","title":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02243813","tracker_url":"publication.php?id=3545","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-06","last_update_date":"2024-06-18","start_date":"2015-03","primary_completion_date":"2024-05-31","completion_date":"2024-05-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3518,"nct_id":"NCT05242029","title":"A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05242029","tracker_url":"publication.php?id=3518","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-01","last_update_date":"2024-02-02","start_date":"2023-12","primary_completion_date":"2024-02","completion_date":"2024-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3623,"nct_id":"NCT05562973","title":"Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05562973","tracker_url":"publication.php?id=3623","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-01","last_update_date":"2024-01-05","start_date":"2025-01","primary_completion_date":"2025-12","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3463,"nct_id":"NCT04052568","title":"Effects of Psilocybin in Anorexia Nervosa","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04052568","tracker_url":"publication.php?id=3463","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-05","last_update_date":"2023-05-06","start_date":"2019-08-26","primary_completion_date":"2022-01-05","completion_date":"2023-04-20","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":22,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3500,"nct_id":"NCT03181529","title":"Effects of Psilocybin in Major Depressive Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT03181529","tracker_url":"publication.php?id=3500","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-11","last_update_date":"2021-12-15","start_date":"2017-08-10","primary_completion_date":"2020-12-02","completion_date":"2020-12-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":27,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3579,"nct_id":"NCT02145091","title":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02145091","tracker_url":"publication.php?id=3579","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-12","last_update_date":"2019-12-30","start_date":"2014-05","primary_completion_date":"2019-12-26","completion_date":"2019-12-26","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Moderately-high dose of psilocybin","type":"DRUG"},{"name":"Moderately-low dose of psilocybin","type":"DRUG"},{"name":"Very-low dose of psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3504,"nct_id":"NCT02971605","title":"Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02971605","tracker_url":"publication.php?id=3504","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-08","last_update_date":"2019-09-10","start_date":"2017-07-01","primary_completion_date":"2018-08-21","completion_date":"2018-08-21","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":13,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3553,"nct_id":"NCT00465595","title":"Psychopharmacology of Psilocybin in Cancer Patients","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT00465595","tracker_url":"publication.php?id=3553","status":"COMPLETED","status_label":"Completed","status_verified_date":"2018-06","last_update_date":"2018-07-19","start_date":"2007-04","primary_completion_date":"2014-12","completion_date":"2016-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":56,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Depressive Symptoms","Anxiety","Cancer"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8a9fa87413d480bac878c14fd3780e61a2c0f2573c87aa67b3913724f16cc960","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3628,"nct_id":"NCT00802282","title":"Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT00802282","tracker_url":"publication.php?id=3628","status":"COMPLETED","status_label":"Completed","status_verified_date":"2016-02","last_update_date":"2016-02-24","start_date":"2009-08","primary_completion_date":"2014-02","completion_date":"2014-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":75,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Intensity of support for spiritual practice","type":"BEHAVIORAL"},{"name":"Number of sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3484,"nct_id":"NCT01988311","title":"Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT01988311","tracker_url":"publication.php?id=3484","status":"COMPLETED","status_label":"Completed","status_verified_date":"2014-05","last_update_date":"2014-05-20","start_date":"2013-05","primary_completion_date":"2014-01","completion_date":"2014-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psilocybin","Hallucinogens","Pharmacologic Actions","Central Nervous System Agents","Therapeutic Uses","Psychotropic Drugs"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2007":1,"2008":1,"2009":1,"2013":1,"2014":1,"2015":1,"2017":2,"2019":1,"2021":2,"2022":3,"2023":2,"2024":5,"2025":6,"2026":3,"2027":1},"statuses":{"Recruiting":13,"Completed":12,"Active, not recruiting":3,"Withdrawn":3},"conditions":{"Healthy":6,"Opioid Use Disorder":3,"Psilocybin":2,"Psychedelic Effects in Healthy Volunteers":2,"Depressive Symptoms":2,"Depression":2,"Major Depressive Disorder":2,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Music Intervention":1,"Obsessive-Compulsive Disorder":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Chronic Low-back Pain":1,"Posttraumatic Stress Disorder":1,"Psychedelic Experiences":1,"Amyotrophic Lateral Sclerosis":1,"Healthy Volunteers":1,"Tobacco Use Disorder":1,"Post Traumatic Stress Disorder":1,"Cannabis Use Disorder":1,"Alcohol Use Disorder":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Nicotine Dependence":1,"Post-Traumatic Stress Disorder":1,"Anorexia Nervosa":1,"Anxiety":1,"Cancer":1,"Hallucinogens":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"e3da1ce8cb4b14f80a762b6f6cadb84535f4c69b15786b698ef1c7179aa721b3","facility":"5510 Nathan Shock Drive","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"4c399ae21c1b15c1a76957dcb18c09f6ab07051151f994333e7109fd67ba663d","facility":"Johns Hopkins School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"be5d63bf40aada157fda0af485fadeddd7eac0c079ecab26a1612289fb4c7fdb","facility":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f728406bf268c1157eadcec1c17036ddef288c0c8a17b0883ee337abaeaac4bc","facility":"Neuroimaging Research Branch, NIDA-IRP","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"8a9fa87413d480bac878c14fd3780e61a2c0f2573c87aa67b3913724f16cc960","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"enrollment":{"sum":1071,"known_trials":31},"registry_checked_at_utc":"2026-10-09 01:24:43"}